Aviva PLC Takes $499,000 Position in Stoke Therapeutics, Inc. $STOK

Aviva PLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 43,955 shares of the company’s stock, valued at approximately $499,000. Aviva PLC owned 0.08% of Stoke Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in STOK. Wellington Management Group LLP grew its holdings in Stoke Therapeutics by 0.9% in the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock worth $904,000 after acquiring an additional 1,148 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares during the period. KLP Kapitalforvaltning AS grew its stake in shares of Stoke Therapeutics by 131.6% in the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock worth $150,000 after purchasing an additional 7,500 shares during the last quarter. MPM Bioimpact LLC grew its stake in shares of Stoke Therapeutics by 1.2% in the first quarter. MPM Bioimpact LLC now owns 693,988 shares of the company’s stock worth $4,615,000 after purchasing an additional 8,162 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $72,000.

Analysts Set New Price Targets

Several research firms have weighed in on STOK. Weiss Ratings upgraded Stoke Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, November 7th. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Wedbush lifted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Finally, Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $26.07 on Friday. The firm has a market capitalization of $1.49 billion, a P/E ratio of 38.91 and a beta of 1.32. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $38.69. The company’s 50-day simple moving average is $26.86 and its 200 day simple moving average is $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total transaction of $925,899.48. Following the completion of the transaction, the director owned 91,585 shares in the company, valued at approximately $1,843,606.05. The trade was a 33.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $300,529.08. Following the completion of the sale, the general counsel directly owned 18,176 shares in the company, valued at approximately $366,064.64. This represents a 45.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 172,895 shares of company stock valued at $4,018,530 in the last 90 days. Corporate insiders own 9.50% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.